Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib proof-of-concept study in moderate-to-severe uncontrolled asthma
2021-002490-26Phase 2Active
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Rilzabrutinib with Placebo (2 arms). Primary endpoint: Proportion of participants with a loss of asthma control event during treatment. Started Aug 2021; status: active.
02
Drugs
rilzabrutinib
03
Conditions
asthma
Beyond the preview
Go deeper on 2021-002490-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002490-26.